Taiho Oncology CEO Tim Whitten: Building Upon Lonsurf, Inqovi

 
• By Joseph Haas
Drug_Design
Otsuka affiliate Taiho has high expectations for its cholangiocarcinoma drug

More from Strategy

More from Business